Talk:Pegaptanib

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pegaptanib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Discovery by Gilead Disputed edit

Latest comment: 10 years ago1 comment1 person in discussion

I believe that it was actually NeXstar (founded by Larry Gold and Craig Tuerk) was the original discoverer. As Gilead didn't acquire NeXstar until 1999 -- a decade after Gold and Tuerk's work -- they shouldn't be credited.

http://www.epo.org/learning-events/european-inventor/finalists/2006/Gold.html

Daen (talk) 00:32, 4 June 2013 (UTC)Reply

Patent expiry edit

Latest comment: 7 years ago2 comments1 person in discussion

US patents 6,113,906 and 5,919,455 on pegaptanib sodium expired around end October 2013. US patents 6,051,698, and 6,011,020, expire in 2015, & 2017. - Rod57 (talk) 06:20, 12 September 2015 (UTC)Reply

US patent 5,932,462 expired Aug 3, 2016. - Rod57 (talk) 09:14, 4 August 2016 (UTC)Reply

Strange results from 2 'identical' phase 3 trials edit

Latest comment: 7 years ago1 comment1 person in discussion

It says the two phase 3 studies were identical but the 2nd year results are very different. What explanations have been given ? - Rod57 (talk) 09:11, 4 August 2016 (UTC)Reply

Add topic